Business Description
ISIN : US24906P1093
Total Employee Number:
14,000Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 1.71 | |||||
Debt-to-EBITDA | 24.86 | |||||
Interest Coverage | 2.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.64 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.5 | |||||
3-Year EBITDA Growth Rate | 57.8 | |||||
3-Year EPS without NRI Growth Rate | -8.5 | |||||
3-Year FCF Growth Rate | -32.6 | |||||
3-Year Book Growth Rate | -27.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.74 | |||||
9-Day RSI | 31.36 | |||||
14-Day RSI | 36.86 | |||||
3-1 Month Momentum % | 29.43 | |||||
6-1 Month Momentum % | 1.73 | |||||
12-1 Month Momentum % | -9.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.07 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 132.07 | |||||
Days Sales Outstanding | 64.72 | |||||
Days Payable | 53.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.89 | |||||
Dividend Payout Ratio | 0.36 | |||||
3-Year Dividend Growth Rate | 8.6 | |||||
5-Year Yield-on-Cost % | 4.87 | |||||
3-Year Average Share Buyback Ratio | 2.5 | |||||
Shareholder Yield % | 2.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 49.52 | |||||
Operating Margin % | 5.05 | |||||
Net Margin % | -14.99 | |||||
EBITDA Margin % | 2.55 | |||||
FCF Margin % | 3.93 | |||||
OCF Margin % | 8.76 | |||||
ROE % | -36.66 | |||||
ROA % | -9.9 | |||||
ROIC % | 4.26 | |||||
3-Year ROIIC % | 3.73 | |||||
ROC (Joel Greenblatt) % | -15.41 | |||||
ROCE % | -6.02 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 7.06 | |||||
PE Ratio without NRI | 12.16 | |||||
PS Ratio | 0.61 | |||||
PB Ratio | 1.61 | |||||
Price-to-Free-Cash-Flow | 15.28 | |||||
Price-to-Operating-Cash-Flow | 6.85 | |||||
EV-to-EBIT | -16.61 | |||||
EV-to-Forward-EBIT | 23.54 | |||||
EV-to-EBITDA | 45.72 | |||||
EV-to-Forward-EBITDA | 8.44 | |||||
EV-to-Revenue | 1.17 | |||||
EV-to-Forward-Revenue | 1.19 | |||||
EV-to-FCF | 29.73 | |||||
Price-to-GF-Value | 0.63 | |||||
Price-to-Projected-FCF | 0.51 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Earnings Yield (Greenblatt) % | -6.02 | |||||
FCF Yield % | 6.56 | |||||
Forward Rate of Return (Yacktman) % | 22.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XRAY
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Dentsply Sirona Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,643 | ||
| EPS (TTM) ($) | -2.75 | ||
| Beta | 0.6593 | ||
| 3-Year Sharpe Ratio | -0.98 | ||
| 3-Year Sortino Ratio | -1.21 | ||
| Volatility % | 44.84 | ||
| 14-Day RSI | 36.86 | ||
| 14-Day ATR ($) | 0.516821 | ||
| 20-Day SMA ($) | 12.0125 | ||
| 12-1 Month Momentum % | -9.83 | ||
| 52-Week Range ($) | 9.405 - 14.86 | ||
| Shares Outstanding (Mil) | 199.35 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dentsply Sirona Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dentsply Sirona Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 184 days | ||
| Annual report for 2026 | 2027-02-26 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 13.78 (-2.89%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 13.78 (-2.89%) | ||
| General meeting for 2026 | 2026-06-02 08:00 | 10.02 (-2.81%) | ||
| Stifel Jaws & Paws Conference | 2026-05-27 15:35 | 9.99 (-2.35%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 11.20 (-5.00%) |
Dentsply Sirona Inc Frequently Asked Questions
Guru Commentaries on NAS:XRAY
We added Dentsply Sirona (XRAY), a leading global dental manufacturing company, to the portfolio. Despite facing challenges in its core capital equipment business due to lower-cost technology alternatives and higher interest rate financing, we are optimistic about the attractive dynamics of the dental market, which includes steady growth and lower reimbursement risk compared to other healthcare segments. Management is executing a strategic reset focused on debt paydown, innovative product development, and portfolio expansion. With these initiatives, we believe XRAY should capitalize on secular growth trends, improve margins, and drive long-term shareholder value.
We purchased DENTSPLY Sirona, Inc. (XRAY), the world’s largest maker of professional dental equipment, whose shares had been left for dead after years of disappointment. At $10.61 against our $26.26 estimate of its private market value, we are buying a global leader that is repairing itself—paying down debt, cutting costs and launching new products—while the market prices in permanent decline.
Dentsply Sirona, Inc. (XRAY) has been laying the groundwork for a turnaround for more than two years, and while the stock has yet to reflect this, we believe the upside potential far outweighs the downside risk. The recent leadership change to CEO Daniel Scavilla, who has a strong record of sales success, is encouraging. His strategies aim to improve margins and free cash flows, which could enhance the company's performance. Despite being among the Fund’s worst performers for the quarter, XRAY's valuation at 6.7X estimated earnings appears extremely discounted, prompting us to remain patient with our position.
Press Release
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
